Physician profile
Samuel Chan
NPI 1508830811
$1,466.79
in general payments reported to CMS, 2019-2025
20 companies · $417 in 2025
The $417 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $19.13 · 2021: $79.05 · 2022: $179 · 2023: $59.94 · 2024: $288 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $351.28 | 2024-2025 | Rs 4i Plus Sequential Stimulator |
| Boston Scientific Corporation | $274.23 | 2019-2025 | General - Pain Management |
| Pfizer INC. | $141.30 | 2019 | |
| Abbvie INC. | $130.65 | 2023-2024 | Botox, Ubrelvy |
| Abbott Laboratories | $98.40 | 2022 | |
| Allergan, INC. | $80.39 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.72 | 2019-2021 | |
| Bioventus LLC | $38.00 | 2021-2022 | |
| Zyla Life Sciences, INC. | $33.13 | 2019 | |
| Si-Bone, INC. | $32.88 | 2025 | |
| Lilly USA, LLC | $32.32 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.47 | 2019 | |
| Ibsa Pharma INC. | $31.11 | 2021-2023 | Tirosint, Licart |
| Shionogi INC | $29.83 | 2019 | |
| Daiichi Sankyo INC. | $22.61 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $17.50 | 2019 | |
| Globus Medical, INC. | $15.67 | 2024 | Allocate |
| Assertio Therapeutics, INC. | $15.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.27 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.